Multinational pharmaceutical companies are expressing disapproval on the report of Phase 4 clinical trial adverse reactions
Multinational pharmaceutical companies are expressing disapproval on the report of Phase 4 clinical trial adverse reactions. They insist that it is difficult to follow the same rules of Ministry of Food and Drug Safety, because there's a difference between domestic and international standard.
On...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
